Jenkins leaving Merck Serono

Merck KGaA (Xetra:MRK) said Annalisa Jenkins will depart as EVP and head of global R&D at its Merck Serono S.A. biopharmaceutical division at the end of March. Jenkins joined Merck Serono in September 2011 as global head of development and medical. She took over as EVP and head of global R&D in October 2013. Belen Garijo, president and CEO of Merck Serono, will be in charge of R&D in the interim. Merck declined to comment on why Jenkins is departing and her next steps. ...